Chemical-structure (Alfuzosin Er 10 mg For Sun 1)
Alfuzosin Hydrochloride
Product Images NDC 33261-994
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 33261-994). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1 (Alfuzosin Er 10 mg For Sun 2)
Figure-2 (Alfuzosin Er 10 mg For Sun 3)
The text is describing the results of a clinical trial comparing the effects of Altuzosin hydrochloride extended-release tablets versus a placebo on an unspecified measure of "mean change". The trial involved 167 participants in the placebo group and 170 participants in the Altuzosin hydrochloride group, treated for 28, 56, or 84 days. The text indicates a statistically significant difference between the two groups, with a p-value of <0.001.*
Figure-3 (Alfuzosin Er 10 mg For Sun 4)
The text describes the results of a study where the mean change in response to treatment was measured over 28, 56, and 84 days. The study included a group of 152 individuals who received a placebo, and a group of 137 individuals who took alfuzosin hydrochloride extended-release tablets. The study found a statistically significant difference in response to treatment between the two groups, indicated by the asterisk and the p-value of less than 0.01.*
Figure-4 (Alfuzosin Er 10 mg For Sun 5)
This appears to be a comparison of the effects of a placebo versus Altuzosin hydrochloride extended-release tablets. There were 150 participants in the placebo group and 151 participants in the Altuzosin group. The graph shows a mean change in something over 84 days of treatment, with a significant difference between the two groups (p < 0.01). However, without further context or information about what the study was measuring, it is difficult to provide a more specific description.*
Figure-5 (Alfuzosin Er 10 mg For Sun 6)
This appears to be a graph comparing the mean change in mL/s between a placebo group (N=167) and a group taking Alfuzosin hydrochloride extended-release tablets (N=170) over the course of 84 days of treatment. The graph shows a significant difference (p<0.001) between the two groups.*
Figure-6 (Alfuzosin Er 10 mg For Sun 7)
This is a medical chart that shows the mean change in urinary flow (mL/s) over time (0, 14, 28, 56 and 84 days) for a placebo group and a group taking alfuzosin hydrochloride extended-release tablets. The data suggests that alfuzosin hydrochloride might improve urinary flow compared to placebo.*
Figure-7 (Alfuzosin Er 10 mg For Sun 8)
The text provides a graph displaying the mean change in mL/s over different days of treatment (14, 28, 56, and 84) for a placebo group and a group taking Altuzosin hydrochloride extended-release tablets. The graph shows no significant difference between the two groups, as indicated by the NS and p > 0.05 notation.*
Image Label (Alfuzosin Er 10 mg For Sun 9)
This is a description of a medication called Alfuzosin ER. The manufacturer for this medication is Sun Pharmaceutical Ind. Ltd in India. The package has 30 extended-release tablets, and the National Drug Code (NDC) is 33261-0994-30. The prescription should be kept out of reach of children and should be stored at a controlled room temperature. The medication is 10mg and contains alfuzosin hydrochloride. It is a generic for Uroxatral. However, the text also includes some typos and discrepancies, which may affect the accuracy of the information provided.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
